Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Quotient Sciences Acquires Arcinova | Contract Pharma

What are you searching for?

Sign in
Breaking News

Quotient Sciences Acquires Arcinova

Acquisition expands Quotient’s services with drug substance, drug product and clinical testing capabilities.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Quotient Sciences has acquired Arcinova, a U.K.-based CDMO. Arcinova has 160 employees, and provides drug substance, drug product and bioanalysis services to more than 200 pharma/biopharma customers worldwide.
 
The acquisition expands Quotient’s services with drug substance, drug product and clinical testing capabilities, along with the 12-month drug development timeline delivered by Quotient’s flagship platform Translational Pharmaceutics.
 
“I’d like to congratulate the Arcinova team on building an exciting business, and I am thrilled to be joining forces. Both businesses are similar in culture and aspire to help customers accelerate molecules from candidate selection through development and on to commercial launch,” said Mark Egerton, Ph.D., CEO of Quotient Sciences. “I’d also like to take this moment to thank our private equity partner, Permira, for supporting our ambitious growth plans.”
 
Professor Ian Shott, CBE, co-founder and executive chairman of Arcinova, said, “Since inception, we set out to build a unique organization that accelerates the development of new medicines for patients in need. We are delighted to move on to the next stage with Quotient as the perfect partner for Arcinova. Deep science, agility, flexibility and the drive for customer service excellence are the cornerstones of both businesses. I look forward to working with the Quotient team and Permira to deliver even greater value for our customers.”
 
As part of the deal, Arcinova’s minority equity partner, BGF, will exit the business.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics